



March 2, 2012

3-D Matrix, Ltd.

**Clinical study with 3DM's technology started at School of Medicine, Keio University**

Regarding self-assembly peptide technology which Massachusetts Institute of Technology granted 3-D Matrix, Ltd. (3DM) an exclusive license of, clinical study has been projected in the endoscope field at Cancer Center, School of Medicine, Keio University; the first clinical study participant was enrolled and the study was started on March 1, 2012.

This clinical study is conducted by Department of Research and Development of less invasive therapy, Cancer Center, School of Medicine, Keio University (Dr. Naohisa Yahagi and Dr. Toshio Uraoka) to evaluate the safety and efficacy for 200 cases in order to prevent postoperative bleeding which is one of accidental symptoms after endoscopic surgery.

Endoscopic mucosal resection and endoscopic submucosal dissection(ESD) are procedures to resect adenoma of gastrointestinal tract and early stage cancer endoscopically and contribute to keeping Quality of Life (QOL) of patients as a less invasive therapy. These procedures have been used in more than 800,000 surgeries of gastrointestinal tract such as esophagus, stomach, and large intestine per year in Japan. However, there are some challenges including hemorrhagic shock upon heavy bleeding, need of blood transfusion and emergency surgery, and longer hospitalization since bleeding from surgical site (ulcer site) can occur sometime after the surgery; simple and effective medical techniques to prevent postoperative bleeding have not been developed yet.

Self-assembly peptide developed by 3DM was confirmed through past animal studies to have the efficacy and safety for hemostasis. This clinical study is conducted by Cancer Center, School of Medicine, Keio University to evaluate the effect to prevent postoperative bleeding from surgical site (ulcer site) after endoscopic mucosal resection and endoscopic submucosal dissection(ESD). 3DM considers that the evaluation of the efficacy and safety of self-assembly peptide in this clinical study leads to developing of new medical products.

3DM promotes research and development and seeking new availability and commercialization of peptide. This clinical study does not influence the earning forecast of 3DM at this moment.